Background

Ischemic stroke is a leading cause of disability. Neuroprotection during the acute phase is critical for minimizing brain damage. Cortexin, a complex of brain peptides, has shown neurotrophic potential.

Study Design

Patients admitted with acute ischemic stroke were randomized to receive standard therapy plus Cortexin (10 mg IM daily for 10 days) or standard therapy alone (placebo).

Clinical Outcomes

Neurological Recovery

The Cortexin group showed a statistically significant improvement in NIHSS (National Institutes of Health Stroke Scale) scores by day 10 compared to controls. Motor function recovery was faster and more complete.

Cognitive Function

Cognitive assessment using the MMSE (Mini-Mental State Examination) revealed that Cortexin-treated patients had better preservation of memory and executive function.

Safety

No significant adverse events were reported, confirming the high safety profile of the peptide bioregulator.

Discussion

Cortexin appears to work by reducing excitotoxicity and oxidative stress in the penumbra (the area surrounding the stroke core), thereby salvaging brain tissue that would otherwise die.

Conclusion

Inclusion of Cortexin in the standard protocol for acute ischemic stroke significantly improves functional and cognitive outcomes.